Patients must not currently be receiving any other investigational agents or any other systemic anti-cancer therapy (including radiation, excluding RANKL inhibitors and bisphosphonates); in event patient recently received any other systemic anti-cancer therapy, patient must be off therapy at least days prior to registration and any therapy-induced toxicity must have recovered to =< grade , except alopecia and =< grade neuropathy which are allowed; any planned radiation therapy must be completed before enrollment onto S Patients must not be planning to require any additional form of systemic anti-tumor therapy while on protocol treatment Patients must be registered within days of the initial metastatic breast cancer diagnosis; first-line standard systemic therapy (chemotherapy, anti-endocrine therapy, anti-HER, or other standard targeted therapy) for metastatic breast cancer must be given or planned to be given; if given before study entry, it cannot have exceeded a duration of months at the time of registration (Note: sequencing of ablative therapy [surgery or SBRT] relative to systemic therapy, for patients randomized to Arm , is at the discretion of the treating physician) Persistence of clinically relevant therapy related toxicity from previous anti-cancer therapy Subject has received anti-cancer Chinese medicine or anti-cancer herbal remedies within days prior to Cycle Day-. Participants who have had prior anti-EGF or anti-HER therapy or cancer-directed chemotherapy Escalation Phase: Subjects may be enrolled with ? lines of prior systemic anti-cancer therapy (but no immunotherapy). Subjects who have had no prior systemic anti-cancer therapy (i.e. first-line therapy) or declined first-line treatment are permitted in the Escalation Phase. For Cohort C only: any prior anti-cancer therapy for advanced melanoma Patients with prior hepatitis B vaccine are permitted (defined as HBsAg-, Anti-HBs+, Anti-HBc-). Recent systemic anti-cancer therapy No prior other anti-cancer therapy, including ACT, for days prior to study administration of atezolizumab Prior cancer therapy or anti-cancer vaccine within weeks of initial study treatment. Concurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti- HER directed therapy directed at management of breast cancer (existing anti-HER therapy can be continued as recently recommended in the National Consensus Guidelines) Anti-platelet therapy, except low-dose aspirin for cardioprotection Ongoing or planned systemic anti-cancer therapy or radiation therapy Participant has received anti-cancer traditional medicine or anti-cancer herbal remedies within days prior to ABBV- dosing. Saw palmetto is considered anti-cancer herbal remedy. Participant with CRPC who has received anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within a period of days prior to Study Day . Participant with AML has received anti-cancer therapy within a period of days or half-lives (whichever is longer; except for immunotherapy where a period of days will be acceptable) prior to Study Day . Except for hydroxyurea which will be allowed during screening and treatment for controlling leukocytosis for AML subjects. Prior standard or investigational anti-cancer therapy, as specified below: Concurrent administration of any other anti-cancer therapy (except male participants with prostate cancer receiving androgen blockade: Bisphosphonates and denosumab are allowed; Most recent anti-cancer therapy days prior to day Patient is concurrently using other anti-cancer therapy. All anti-cancer therapy must be discontinued prior to day one of study treatment. ARM A: Systemic anti-cancer therapy =< weeks prior to registration ARM B: Systemic anti-cancer therapy =< weeks prior to registration Use of other anti-cancer therapies within five half-lives from the previous dose of the prior anti-cancer therapy preceding enrollment and during the study Prior investigational anti-cancer therapy within weeks prior to day Anti-angiogenic therapy within the last month GVHD therapies: Any systemic drug used for GVHD must be stopped > weeks prior to CTL infusion to confirm that GVHD recurrence is not observed (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD (rituximab), anti-tumor necrosis factor [anti-TNF], anti-interleukin [anti-IL] or anti-interleukin receptor [anti-ILR], systemic steroids) Concurrent administration of any other anti-cancer therapy within days of starting protocol therapy and during the course of this study (bisphosphonates and RANK ligand inhibitors are allowed) GVHD therapies: Any drug used for GVHD must be stopped > weeks prior to CTL infusion (e.g. calcineurin inhibitors, methotrexate or other chemotherapy drugs, mycophenolyate, rapamycin, thalidomide, or immunosuppressive antibodies such as anti-CD (rituximab), anti-TNF, anti-IL or anti-ILR) Anti-tumor therapy within days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permitted Anti-androgen receptor antagonist therapy must be bicalutamide. Subjects already started on other anti-androgens must be willing to switch over to bicalutamide. Did not receive any anti-cancer treatment since the last dose of MK- No planned concomitant, non-protocol directed anti-cancer therapy Any anti-cancer therapy within weeks of study drug Standard treatment interrupted, except if anti-HER therapy No prior systemic anti-cancer therapy for advanced ER+ disease Evidence of active infection that requires anti-bacterial, anti-viral, or anti-fungal therapy =< days prior to initiation of study drug therapy No prior systemic anti-cancer therapy for advanced ER+ disease. However, subjects who are HER- positive and responsive to anti-HER- therapy (e.g. Herceptin), are encouraged to remain on anti-HER- therapy and not enroll in this trial. Concomitant use of any anti-cancer therapy or radiation therapy, or any other investigational agent Prior anti-HER targeting therapy Received systemic anti-cancer therapy within days of Week , Day of study treatment. Recent cancer-directed therapies: Radiotherapy (RT) within weeks, chemotherapy or other systemic anti-cancer therapy within weeks, or prior anti-angiogenic treatment (e.g., bevacizumab) within weeks prior to starting treatment More than previous systemic anti-cancer therapy line Patients receiving anti-cancer therapy within days before MSC treatment Concurrent anti-platelet therapy Alternative anti-cancer treatment Anti-cancer therapy =< days prior to randomization Patients who are currently taking any anti-cancer directed therapy; steroids are not considered anti-cancer therapy For the currently diagnosed breast cancer, any previous systemic anti-cancer treatment (for example, neoadjuvant or adjuvant), including but not limited to, chemotherapy, anti-HER therapy (for example, trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, neratinib, or other tyrosine kinase inhibitors), hormonal therapy, OR anti-cancer radiation therapy (RT) (intra-operative radiotherapy as a boost at the time of primary surgery is acceptable) No prior systemic anti-cancer therapy for advanced disease. Patient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer Note: GVHD therapies such as calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate mofetil, rapamycin, or immunosuppressive antibodies (such as anti-tumor necrosis factor-? [TNF?], anti-interleukin- [IL-], or anti-interleukin- receptor [IL R]) within weeks prior to leukapheresis Receiving or have received systemic anti-cancer therapy within days prior to starting study treatment Concurrent administration of any other anti-tumor therapy Uncontrolled cancer requiring the institution of new anti-cancer therapy during the study period Any systemic anti-cancer treatment out of allowed timelines Prior anti-tumor therapy within weeks Ongoing or planned systemic anti-cancer therapy or radiation therapy Any concurrent anti-cancer therapy, excluding hormonal therapy for prostate or breast cancer Specific anti-cancer therapy within weeks of study start Prior therapy with anti-angiogenic agents is permitted Other anti-cancer therapy up to days prior to enrollment, with the exception of hydroxyurea, which can be given up to days prior to enrollment. Has received systemic anti-cancer therapy within the days prior to randomization Anti-cancer chemotherapy, experimental cancer therapy including clinical trial, or cancer immunotherapy within weeks prior to the first dose of the investigational drug. Concurrent therapy with any other non-protocol anti-cancer therapy Being treated with anti-TNF therapies or has been treated with an anti-TNF therapy within half-lives of randomization. Prior EGFR-targeted regimen, anti-HER, anti-HER, or anti-HER therapy Prior anti-androgens are permitted but not required ( week washout from anti-androgens) Currently receiving any anti-tumor treatments, or less than days prior to enrollment since ending anti-tumor treatment Has received other anti-cancer therapy within the following specified intervals prior to Day : Concurrent treatment with other anti-cancer therapy Prior anti-estrogen therapy. Subjects with breast cancer must have been treated with at least two FDA-approved anti-HER directed therapies (more than two is also permissible), and subjects with gastric and gastroesophageal junction cancers must have been treated with at least one FDA-approved anti-HER directed therapy (more than one is also permissible); and all subjects must have refractory or relapsed/progressive disease during or following their last prior anti-HER directed therapy. Subjects enrolling in the study who have non-breast, non-gastric, non-gastroesophageal junction cancers do not require any prior treatment with anti-HER therapy if there is no FDA-approved anti-HER agent for their specific cancer type, but they must have refractory or relapsed/progressive disease during or following their last prior anti-cancer therapy. Anti-tumor therapy within days of study day Concurrent anti-cancer treatment, except anti-hormonal therapy for subjects with hormone receptor positive breast cancer Prior treatment with anti-HER therapy, except trastuzumab or lapatinib Therapeutic anti-coagulative or long term anti-platelet treatment. Anti-tumor therapy within days of study Day Concurrent therapy with any other non-protocol anti-cancer therapy For Arms A and C: Treatment with any FGFR inhibitor. For Arm B: Treatment with any anti-cancer therapy (for biological anti-cancer therapies see criteria below) during the preceding weeks or within half-lives of the therapy, whichever is longer. Prior anti-cancer therapy Anti-cancer treatment days prior to study Day , except in Arm B expanded cohort temozolomide therapy is allowed Anti-tumor therapy Previously treated with an anti-Dickkopf- (anti-DKK-) or antibody therapy, or have had a significant allergy to a known pharmaceutical therapy that, in the opinion of the Investigator, poses an increased risk to the patient Patients on concurrent anti-cancer therapy other than that allowed in the study Active infection requiring systemic anti-microbial treatment (including antibiotics, anti-fungals, and anti-viral agents) Evidence of active infection, requiring parenteral anti-bacterial, anti-viral or anti-fungal therapy < days prior to administration of study medication Participants requiring anti-hyperglycemic therapy Previously received E anti-cmet, or anti-angiogenic therapy (prior anti-angiogenic therapy is permitted in Phase Ib only); Anti-tumor therapy within days of study day including chemotherapy, antibody therapy, retinoid therapy, or other investigational agent Less than (<) weeks since the last anti-tumor therapy prior to Day of study treatment Concurrent therapy with any other non-protocol anti-cancer therapy Patients on concurrent anti cancer therapy other than that allowed in the study. No prior anti-cancer treatment No prior treatment with systemic anti-cancer therapy for SCCHN unless protocol-defined conditions are met. Anti-cancer therapy within days prior to starting on therapy No other investigational or standard anti-tumor therapy allowed Ongoing anticoagulant, statin and/or anti-platelet therapy Patients who are able to comply with the anti-emetic therapy Must have received systemic therapy for their breast cancer (anti-estrogen and/or chemotherapy)\r\n* Chemotherapy must be complete prior to entry\r\n* Anti-estrogen therapy may be ongoing Concurrent anti-cancer therapy Patients must not be receiving anti-myeloma therapy (including maintenance therapy) Active systemic infection requiring ongoing intervention, including but not limited to oral and intravenous antibiotics, anti-fungals, anti-parasites, anti-virals Patients deemed to require anti-estrogen therapy for treatment of their breast cancer can continue anti-estrogen therapy during vaccinations Patients must be anti-angiogenic therapy naive Participants who have already received anti-VEGF or investigational anti-angiogenic therapy for glioblastoma Had at least prior anti-MM regimen and no more than prior anti-MM regimens. Induction therapy followed by stem cell transplant and consolidation/maintenance therapy will be considered as anti-MM regimen. Anti-androgenic therapy within days prior to enrollment Persistent acute toxicities from prior anti-cancer therapy.